Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

Malcolm A. Smith, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, John M. Maris, Stephen T. Keir, Christopher L. Morton, C. Patrick Reynolds, Min H. Kang, Janine Arts, Tarig Bashir, Michel Janicot, Raushan T. Kurmasheva, Peter J. Houghton

Producción científica: Articlerevisión exhaustiva

23 Citas (Scopus)


JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC 50 (0.85μM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

Idioma originalEnglish (US)
Páginas (desde-hasta)329-332
Número de páginas4
PublicaciónPediatric Blood and Cancer
EstadoPublished - ago 2012
Publicado de forma externa

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Profundice en los temas de investigación de 'Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program'. En conjunto forman una huella única.

Citar esto